Skip to main content
Article thumbnail
Location of Repository

Influence of vitamin D supplementation on plasma lipid profiles: A meta-analysis of randomized controlled trials

By Hao Wang, Ning Xia, Yang Yang and Dao-Quan Peng

Abstract

Observational studies have shown that low serum levels of vitamin D have been associated with an atherogenic lipid profile. However, the intervention studies gave divergent results. We conducted a meta-analysis of randomized controlled trials that evaluated the effects of vitamin D supplementation on blood lipids. A systematic literature search was conducted via MEDLINE, Cochrane library, and EMBASE for randomized controlled clinical trials assessing the effects of vitamin D supplementation on lipids. The mean change in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) from baseline was treated as a continuous variable. In all, 12 clinical trials consisting of 1346 participants were included in the analysis. The pooled estimate of effect for vitamin D supplementation on LDL-C was 3.23 mg/dl (95% confidence interval, 0.55 to 5.90 mg/dl). No statistically significant effects for vitamin D supplementation were observed for TC, HDL-C and TG (differences in means were 1.52 mg/dl (-1.42 to 4.46 mg/dl), -0.14 mg/dl (-0.99 to 0.71 mg/dl) and -1.92 mg/dl (-7.72 to 3.88 mg/dl) respectively). The lipid modulating effects of vitamin D supplementation should be further investigated though large-scale, randomized trials with adequate doses which can effectively elevated the active form of vitamin D in plasma and with proper population which has hyperlipemia as an inclusion criterion

Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3325888
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2011). 24, 25-dihydroxycholecalciferol but not 25-hydroxycholecalciferol Wang et al.
    2. (2009). A: A double-blind, randomized, placebocontrolled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med J Br Diabet Assoc
    3. (2011). A: Effects of vitamin D supplementation on 25-hydroxyvitamin D, high-density lipoprotein cholesterol, and other cardiovascular disease risk markers in subjects with elevated waist circumference.
    4. (2005). AD: Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochim Biophys Acta
    5. (2010). AD: The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia
    6. (2010). AD: The effect of vitamin D replacement on markers of vascular health in stroke patients -A randomised controlled trial. Nutr Metab Cardiovasc Dis
    7. (1992). Cardiovascular risk factors during estrogen-norethindrone and cholecalciferol treatment. Arch Intern Med
    8. (2006). CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet
    9. (2003). Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate.
    10. (2000). Effect of vitamins on the lipid profile of patients on regular hemodialysis.
    11. (2001). Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women.
    12. (2009). Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther
    13. (1992). Erdogan Y: Effects of 1,25 (OH)2D3 treatment on lipid levels in uremic hemodialysis patients.
    14. (2006). Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes.
    15. (2011). Fang X: Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: Association with estrogen receptor-(alpha) genotypes. Menopause
    16. (2010). Figenschau Y: No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year.
    17. (2010). Franco OH: Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas
    18. (2009). Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int
    19. (2011). Grimnes G: High serum 25-hydroxyvitamin D concentrations are associated with a favorable serum lipid profile.
    20. (1996). HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials
    21. (2000). Holick MF: Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr
    22. (2008). Holick MF: Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?
    23. (2008). Impact of treatment with oral calcitriol on glucose intolerance and dyslipidemia (s) in hemodialysis patients. Saudi J Kidney Dis Transplant Offic Publ Saudi Center Organ Transplant Saudi Arabia
    24. (2003). Naaman R: Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women.
    25. (2005). Putting cardiovascular disease and vitamin D insufficiency into perspective.
    26. (1997). RH: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the
    27. (1997). Saarikoski S: Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy.
    28. (2009). Serum cholesterol and expression of ApoAI, LXRbeta and SREBP2 in vitamin D receptor knock-out mice.
    29. (2010). Sesso HD: Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med
    30. (2010). TE: Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: Results from the women’s health initiative.
    31. (2011). The role of vitamin D in dyslipidemia and cardiovascular disease. Curr Pharm Des
    32. (1987). Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance-a prospective randomized double-blind study. Acta Med Scand
    33. (2007). Tremblay A: Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations.
    34. (1992). Variance imputation for overviews of clinical trials with continuous response.
    35. (2008). Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation
    36. (2011). Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res
    37. (2007). Vitamin D deficiency.
    38. (2009). Vitamin D supplementation does not affect serum lipids and lipoproteins in Pakistani immigrants.
    39. (2009). Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.